DeepCyte Launches With $1.5M Seed to Apply Single-Cell AI to Drug Toxicity Risk

New updates have been reported about DeepCyte.

DeepCyte has formally launched as a techbio company focused on AI-driven toxicology for drug development, backed by $1.5 million in seed funding and dual headquarters in Delaware and Copenhagen. The company is targeting one of biopharma’s biggest value‑destruction drivers—unpredicted drug toxicity that leads to costly trial failures and withdrawals—by providing tools that detect, predict, and explain toxicity in human cells at single‑cell resolution.

At the core of DeepCyte’s strategy is MetaCore, a high‑throughput single‑cell metabolomics platform that uses laser-based sampling and mass spectrometry to generate detailed molecular profiles across heterogeneous cell populations. These profiles are designed to produce large, AI-ready datasets with minimal sample prep and at a cost point intended to support scale in pharma workflows, aligning with regulators like the FDA and EMA that are pushing for human‑relevant, mechanism‑aware safety testing. DeepCyte’s first AI product, DeeImmuno, is trained on proprietary single‑cell metabolomics atlases to classify toxicity, find biomarkers, and infer mechanisms; in tests on 100 held‑out drugs, it identified 17 detailed toxicity mechanisms with 94% accuracy, suggesting potential to materially improve early risk assessment versus animal models and bulk assays. CEO and co‑founder Theodore Alexandrov, who previously built the METASPACE cloud platform and co‑founded SCiLS (later acquired by Bruker), is positioning DeepCyte to monetize through partnerships with biopharma teams seeking to de‑risk pipelines and reduce reliance on legacy toxicology methods, with Board Chair Carl J. G. Evertsz bringing additional commercialization and medtech experience to support scaling and industry adoption.